Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC
NCT05123625 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2025-08-05
Summary
There is no consensus on the need for lymph node dissection in radical cystectomy (RC) for high-risk non-muscular invasive bladder cancer (NMIBC). Investigators divided participants at high risk of NMIBC without enlarged lymph nodes as indicated by pelvic MRI into two groups 1:1. One group of participants underwent RC combined with lymph node dissection and the other group of participants only underwent RC. The incidence of complications and PFS/OS at 1, 3, and 5 years were compared.
Conditions
Interventions
- PROCEDURE
-
Reduce surgical procedures
In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
Sponsors & Collaborators
-
The Second Affiliated Hospital of Kunming Medical University
collaborator OTHER -
Tianjin Medical University Second Hospital
collaborator OTHER -
RenJi Hospital
collaborator OTHER -
First Affiliated Hospital Xi'an Jiaotong University
collaborator OTHER -
The First Affiliated Hospital with Nanjing Medical University
lead OTHER
Principal Investigators
-
Qiang Lu, PhD · The First Affiliated Hospital with Nanjing Medical University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-01
- Primary Completion
- 2027-06-30
- Completion
- 2028-06-30
Countries
- China
Study Locations
More Related Trials
-
Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy
NCT07053722 ·Status: NOT_YET_RECRUITING
-
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
NCT06290687 ·Status: RECRUITING ·Phase: PHASE2
-
S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
NCT01224665 ·Status: COMPLETED ·Phase: NA
-
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
NCT06735287 ·Status: RECRUITING ·Phase: NA
-
A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer
NCT05016973 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
NCT05742867 ·Status: COMPLETED
-
Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective Study
NCT04194112 ·Status: COMPLETED ·Phase: NA
-
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
NCT02968732 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer
NCT07008833 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy
NCT07053748 ·Status: NOT_YET_RECRUITING
-
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
NCT05445648 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Medical Imaging in Bladder Tumors by MRI
NCT06033040 ·Status: RECRUITING
-
The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
NCT05096533 ·Status: UNKNOWN
-
Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy
NCT03049410 ·Status: COMPLETED ·Phase: NA
-
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
NCT06287541 ·Status: RECRUITING ·Phase: NA
-
Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer
NCT02514408 ·Status: WITHDRAWN
-
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
NCT05401279 ·Status: UNKNOWN ·Phase: PHASE2
-
Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma)
NCT03230201 ·Status: UNKNOWN ·Phase: NA
-
Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy
NCT06986304 ·Status: RECRUITING
-
HIPEC After Radical Cystectomy for High Risk Bladder Cancer
NCT03514888 ·Status: COMPLETED ·Phase: NA
-
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
NCT06126796 ·Status: COMPLETED
-
Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer
NCT04726735 ·Status: COMPLETED
-
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07180212 ·Status: RECRUITING ·Phase: NA
-
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
NCT05943379 ·Status: RECRUITING ·Phase: PHASE2
-
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
NCT06138561 ·Status: RECRUITING